Trade Mark Journal No.2026/012 20 March 2026
UK00004348561 3 March 2026 (5)
Mark 1

Mark 2

Mark 3

Mark 4

- Class 5
- Pharmaceuticals; therapeutics; pharmaceuticals and therapeutics for the treatment of autoimmune diseases; pharmaceuticals and therapeutics for the treatment of inflammatory diseases and conditions; pharmaceuticals and therapeutics for the treatment of irritable bowel disease, metabolic disorders, psoriasis, psoriatic arthritis, hidradenitis suppurativa and ankylosing spondylitis.
Re-Aim Therapeutics Ltd
Representative: Kilburn & Strode LLP